Affymetrix Revenues Rebound as Biochip Sector Reports Strong Second Quarter | GenomeWeb

With market leader Affymetrix rebounding from a slide, and a slew of product development projects and collaborations, quarterly earnings reports largely indicate that the microarray and biochip sector is continuing to grow rapidly.

In the last week of July, Affymetrix reported second-quarter revenues of $49.5 million, a figure at the high end of the company’s earlier-reduced projections of between $44 million and $50 million.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.